We can't find the internet
Attempting to reconnect
19080.2 PFLS-LS
Selective small molecule LFA-1 inhibitors to restore self-protective immune privilege in non-infectious posterior uveitis.
Zusammenfassung
Selective small molecule LFA-1 inhibitors to restore self-protective immune privilege in non-infectious posterior uveitis.
Weitere Texte
Abstract
Non-infectious posterior uveitis is a sight-threatening inflammatory eye disease which accounts for 10% of preventable blindness, despite currently available therapies. There is a high need for medications which not only provide sight-saving efficacy yet also lasting protection against disease. The goal of this project is to advance such potential therapy, a newly discovered class of small molecule compounds selectively inhibiting the integrin lymphocyte function-associated antigen-1 (LFA-1), to pre-clinical proof-of concept (PoC) and drug candidate status. The current project is expected to be followed by toxicology studies enabling clinical entry and subsequent clinical exploration of an innovative sight-saving regimen, aiming to restore the eyes natural immune privilege for potential freedom of disease.
Beteiligte
Albrecht-Georg Schmidt
Wirtschaftspartner
albrecht.schmidt@allocyte-pharma.com
AlloCyte Pharmaceuticals AG Albrecht-Georg Schmidt Hochbergerstrasse 60C 4057 Basel BS CH
Daniel Gygax
Kontaktperson
daniel.gygax@fhnw.ch
FHNW Fachhochschule Nordwestschweiz Hochschule für Life Sciences Daniel Gygax Gründenstrasse 40 4132 Muttenz BL CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2016-09-30
- Enddatum
- 2018-10-31
- Bewilligte Gesamtkosten
- CHF 395320.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%